Disc Medicine to present hematology data at EHA 2025, including findings on bitopertin and DISC-0974 for blood disorders.
Quiver AI Summary
Disc Medicine, Inc. announced it will present data from its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan from June 12-15, 2025. The presentations will include results from the HELIOS long-term extension trial of bitopertin for erythropoietic protoporphyria, additional durability data from the Phase 1b study of DISC-0974 in myelofibrosis anemia, and updates from studies involving DISC-3405 in healthy volunteers. CEO John Quisel highlighted the progress as the company approaches significant milestones in the second half of 2025. A conference call to discuss the data will take place on June 16 at 8:00 am ET.
Potential Positives
- Disc Medicine will present significant data supporting the potential of bitopertin as the first disease-modifying treatment for erythropoietic protoporphyria (EPP) at a major conference, highlighting their advancements in hematology.
- The company is showcasing additional data from its Phase 1b study of DISC-0974, which could enhance its profile in treating anemia of myelofibrosis (MF), indicating ongoing research and development progress.
- New data from DISC-3405 studies supports its progression into a Phase 2 study in polycythemia vera, indicating a broadening therapeutic pipeline and potential for expansion into diseases of iron overload.
- Management's planned corporate update call demonstrates transparency and engagement with stakeholders regarding company milestones and research developments.
Potential Negatives
- Management's emphasis on "steady progress" across the pipeline may indicate past issues or delays in development that need to be addressed.
- The press release heavily relies on forward-looking statements, which carry inherent risks and uncertainties, possibly leading to investor skepticism regarding the company's future performance.
- The mention of potential risks related to capital adequacy and clinical trial initiation may raise concerns about the company's financial stability and developmental timeline.
FAQ
What is the focus of Disc Medicine, Inc.?
Disc Medicine, Inc. focuses on developing novel treatments for serious hematologic diseases.
When will the EHA 2025 Congress take place?
The EHA 2025 Congress will occur from June 12-15, 2025, in Milan, Italy.
What data will be presented at the EHA Congress?
Data will be presented from the HELIOS trial, DISC-0974 studies, and DISC-3405 studies.
How can I register for the corporate update call?
You can register for the corporate update call on Disc's Events and Presentations page on their website.
What are some key presentations scheduled during the conference?
Key presentations include studies on bitopertin, DISC-0974, and DISC-3405 focusing on anemia and iron overload.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRON Insider Trading Activity
$IRON insiders have traded $IRON stock on the open market 84 times in the past 6 months. Of those trades, 0 have been purchases and 84 have been sales.
Here’s a breakdown of recent trading of $IRON stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED has made 0 purchases and 27 sales selling 370,551 shares for an estimated $20,108,065.
- MONA ASHIYA has made 0 purchases and 27 sales selling 370,551 shares for an estimated $20,108,065.
- JOHN D QUISEL (Chief Executive Officer) has made 0 purchases and 10 sales selling 51,197 shares for an estimated $3,205,957.
- WILLIAM JACOB SAVAGE (Chief Medical Officer) has made 0 purchases and 8 sales selling 27,079 shares for an estimated $1,669,248.
- RAHUL KHARA (Chief Legal Officer) has made 0 purchases and 6 sales selling 16,161 shares for an estimated $950,598.
- PAMELA STEPHENSON (Chief Commercial Officer) sold 3,137 shares for an estimated $171,217
- JEAN M. FRANCHI (Chief Financial Officer) sold 3,136 shares for an estimated $171,162
- WILLIAM RICHARD WHITE has made 0 purchases and 3 sales selling 1,957 shares for an estimated $126,489.
- JONATHAN YEN-WEN YU (Chief Operating Officer) sold 1,610 shares for an estimated $87,873
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IRON Hedge Fund Activity
We have seen 88 institutional investors add shares of $IRON stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,358,133 shares (+72.8%) to their portfolio in Q1 2025, for an estimated $67,417,722
- WELLINGTON MANAGEMENT GROUP LLP added 948,094 shares (+67.9%) to their portfolio in Q1 2025, for an estimated $47,063,386
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 812,235 shares (-45.2%) from their portfolio in Q4 2024, for an estimated $51,495,699
- POINT72 ASSET MANAGEMENT, L.P. removed 742,423 shares (-98.2%) from their portfolio in Q4 2024, for an estimated $47,069,618
- LOGOS GLOBAL MANAGEMENT LP removed 735,000 shares (-78.6%) from their portfolio in Q4 2024, for an estimated $46,599,000
- JPMORGAN CHASE & CO added 698,321 shares (+1144.5%) to their portfolio in Q1 2025, for an estimated $34,664,654
- JANUS HENDERSON GROUP PLC added 467,988 shares (+62.4%) to their portfolio in Q4 2024, for an estimated $29,670,439
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IRON Analyst Ratings
Wall Street analysts have issued reports on $IRON in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 03/18/2025
To track analyst ratings and price targets for $IRON, check out Quiver Quantitative's $IRON forecast page.
Full Release
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteers
Management will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST
WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.
“As we progress toward major company milestones in the second half of 2025, this year’s EHA presentations showcase steady progress across our pipeline,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We plan to share data from the HELIOS long-term extension trial, further supporting bitopertin’s potential profile as the first disease-modifying treatment for EPP. We’ll also present additional durability data and new analyses from the Phase 1b study of DISC-0974 in patients with MF anemia, along with new data from DISC-3405 in healthy volunteers that supports its progression into a Phase 2 study in polycythemia vera in the first half of this year and its broader potential in diseases of iron overload.”
Management will host a call to review the presented data on June 16 at 8:00 am ET. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/)
Details of Presentations and Abstracts
The full abstracts are now available through the EHA conference website. Pursuant to Disc Medicine practice, the abstracts published today contain previously presented data, and new data and analyses are reserved for presentation at the conference.
Bitopertin Poster Presentations:
Abstract Number:
PS2210
Title:
Results from the HELIOS Study: A Phase 2, Open-Label, Long-Term Extension Study of Bitopertin in Erythropoietic Protoporphyria
Date / Time:
Saturday, June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author:
Melanie Chin
DISC-0974 Poster Presentations:
Abstract Number:
PF856
Title:
A Phase 1b/2 Study of DISC-0974, An Anti-Hemojuvelin Antibody, In Patients with Myelofibrosis and Anemia
Date / Time:
Friday, June 13, 6:30 pm CEST / 12:30 pm ET
Presenting Author:
Sima Bhatt
Abstract Number:
PS1845
Title:
DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis: Laboratory Correlates of Major Anemia Response
Date / Time: Saturday,
June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author:
Ayalew Tefferi
Abstract Number:
PS1814
Title:
Anti-Hemojuvelin Monoclonal Antibody Further Enhances Hematologic Response to ESA and/or Luspatercept in Mice
Date / Time: Saturday,
June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author:
Min Wu
DISC-3405 Poster Presentations:
Abstract Number:
PF1216
Title:
An Iron Pulse Study to Assess Oral Iron Absorption Following Treatment with DISC-3405 in Healthy Volunteers
Date / Time:
Friday, June 13, 6:30 pm CEST / 12:30 pm ET
Presenting Author:
Guowen Liu
Abstract Number:
PS2207
Title:
Single- and Multiple- Ascending Doses of DISC-3405, A Recombinant Humanized Antibody Targeting TMPRSS6, Increased Hepcidin and Reduced Iron and Hematocrit in Healthy Volunteers
Date / Time:
Saturday, June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author:
Marcus Carden
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit
www.discmedicine.com
.
Disc Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: Disc’s future product development plans and projected timelines for the presentation of data, initiation and completion of preclinical and clinical trials and other activities. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
Christina.tartaglia@precisionaq.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
